explore -WSS

explore

author：fashion 2025-09-03 03:43:12 - browse：69284

Obesity conference attendees with a pink and blue Wegovy sign hanging from the ceiling above. -- obesity coverage from STAT — Wegovy, the obesity drug, was inescapable at the ObesityWeek conference in Dallas. Elaine Chen

DALLAS — Here at ObesityWeek, one of the largest conferences on obesity, Novo Nordisk and Eli Lilly are displaying more than a dozen studies that together carry the message: Our blockbuster weight loss treatments will be worth it for society.

But experts point out that much of this company-funded research does not include the cost of the drugs themselves, which sell at more than $10,000 per year in the U.S. and are meant to be taken indefinitely.

The two major pharmaceutical companies have seen interest skyrocket for their GLP-1-based drugs like Ozempic, Wegovy, and Mounjaro, a new generation of medications that can cut substantial amounts of weight. But insurance plans have been slow to grant wide access to obesity treatments, concerned that the vast amount of people eligible to take them, along with their high price, could lead to significant financial strain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Diversify hospital leadership teams to protect BIPOC patient health

WSS

Excited delirium, Elijah McClain, and emergency physicians

Will General Catalyst be the first of many hospital takeovers?

Wegovy’s successful heart trial raises vital question about weight loss

Excited delirium, Elijah McClain, and emergency physicians

Sanofi CEO defends move to abandon profit guidance, boost research

Sanofi CEO defends move to abandon profit guidance, boost research

entertainment

explore

leisure time

In age of alternative facts, a scholarly course on calling out crap

Friends ask where James Watson's attitudes about race came from

Medical records are filled with copy

Anavex keeps shifting the goalposts in its clinical trials

Peter Hotez and the public health issue of online harassment

FDA approves potent Eli Lilly obesity drug, Zepbound

Virginia high school admissions case could be legal follow

FDA approves potent Eli Lilly obesity drug, Zepbound

Walensky prepares to leave CDC — and Congress — behind

Biotech incubator Curie.Bio graduates its first startup

entertainment

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

A clever new way to fix Medicaid and graduate medical education

FDA approves potent Eli Lilly obesity drug, Zepbound

MoonLake credibility takes another hit with mid

FDA approves potent Eli Lilly obesity drug, Zepbound

A clever new way to fix Medicaid and graduate medical education

leisure time

hotspot

focus

entertainment